Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3586-3592

  Johnson, Richard ^a   Jiskoot, Wim ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biopharmaceuticals characterization; Immunology; In silico modeling; In vitro in vivo correlations (IVIVC); Protein aggregation

Indexed keywords

ALPHA INTERFERON; ENDOTOXIN; PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ALGORITHM; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPUTER MODEL; CYTOKINE PRODUCTION; DENDRITIC CELL; DISULFIDE BOND; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN AGGREGATION; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 84865359350     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23248     Document Type: Note

References (41)

1. Pozdnyakova O, Guttormsen H-K, Lalani FN, CarrollMC, Kasper, DL., 2003. Impaired antibody response to group B streptococcal typ III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 170:84-90.
2. Dempsey PW, Allison MED, Akkaraju S, Goodnow, CC, Fearon, DT. 1996. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 271:348-350.
3. Villiers M-B, Villiers CL, Laharie A-M, Marche PN. 1999. Amplification of the antibody response by C3b complexed to antigen through an ester link. J Immunol 162:3647-3650.
4. Knopf PM, Rivera DS, Hai S-H, McMurry, J, Martin, W, De Groot, AS. 2008. Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol 86:221-225.
5. Creagh EM, O'Neill LAJ. 2006. TLRs, NLRs, and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27:352-357.
6. Rosenberg AS. 2006. Effect of protein aggregates: An immunological perspective. AAPS J 8:e501-e507.
7. Dasgupta S, Bayry R, Andre S, Dimitov, JD, Kaveri, SV, Lacroix-Desmazes, S. 2008. Auditing protein therapeutics management by professional APCs: Toward prevention of immune responses against therapeutic proteins. J Immunol 181:1609-1615.
8. + regulatory T cells: Differentiation, specification, subtypes. Nat Immunol 10:689-695.
9. Parker DC. 1993. T cell-dependent B cell activation. Annual Rev Immunol 11:331-360.
10. Hardwood NE, Batista FD. 2010. Early events in B cell activation. Annual Rev Immunol 28:185-210.
11. Wing K, Sakaguchi S. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7-13.
12. Lazarski CA, Chaves FA, Jenks SA, Wu, S, Richards, KA, Weaver, JA, Sant, AJ. 2005. The kinetic stability of MHC class II-peptide complexes is a key parameter that dictates immunodominance. Immunity 23:29-40.
13. Tangri S, Mothe BR, Eisenbraun J, Sidney, J, Southwood, S, Briggs, K, Zinckgraf, J, Newman, M, Chesnut, R, LiCalsi, C, Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174:3187-3196.
14. Petrovski N, Brusic V. 2006. Bioinformatics for the study of autoimmunity. Autoimmunity 39:635-643.
15. DeGroot AS, McMurry J, Moise L. 2007. Prediction of immunogenicity: In silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:1-7.
16. Iwai LK, Yoshida M, Sydney J, Shikanai-Yasuda, MA, Goldberg, AC, Juliano, MA, Hammer, J, Juliano, L, Sette, A, Kalil, J, Travassos, LR, Cunha-Neto, E. 2003. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol Med 9:9-12.
17. DeGroot AS, Jesdale B, Martin W, SaintAubin, C, Sbai, H, Bosma, A, Lieberman, J, Skowron, G, Mansourati, F, Mayer, KH. 2003. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 21:4486-4504.
18. Koren E, De Groot AS, Jawa V, Beck, KD, Boone, T, Rivera, D, Li, L, Mytych, D, Koscec, D, Weeraratne, D, Swanson, S, Martin, W. 2007. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:26-32.
19. Tatarewicz S, Wei X, Gupta S, Masterman, D, Swanson, SJ, Moxness, MS. 2007. Development of a maturing T cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27:620-627.
20. Li P, Haque A, Blum JS. 2002. Role of disulfide bonds in regulating antigen processing and epitope selection. J Immunol 169:2444-2450.
21. Moss CX, Matthews SP, Lamont DJ, Watts C. 2005. Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J Biol Chem 280:18498-18503.
22. Tillman HC, Kuhn B, Kranzlin B, Sadick, M, Gross, J, Gretz, N, Pill, J. Efficacy and immunogenicity of novel erythropoietin agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 69:60-67.
23. Agrawal NJ, Kumar S, Wang X, Helk, B, Singh, SK, Trout, BL., 2011. Aggregation in protein-based biotherapeutics: Computational studies and tools to identify aggregation-prone regions. J Pharm Sci 100:5081-5095.
24. Kumar S, Singh SK, Wang X, Rup B, Gill, D. 2011. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 28:949-961.
25. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2010. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem 114:6614-6624.
26. Jaber A, Baker M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 43:1256-1261.
27. Stickler M, Rochanayon N, Razo J, Mucha, J, Gebel, W, Faravashi, N, Chin, R, Holmes, S, Harding, FA. 2004. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol Sci 77:280-289.
28. + T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 3:991-1000.
29. Egger M, Jurets A, Wallner M, Briza, P, Ruzek, S, Hainzl, S, Pichler, U, Kitzmuller, C, Bohle, B, Huber, CG, Ferreira, F. 2011. Assessing protein immunogenicity with a dendritic cell line-derived endosomal degardome. PLoS One 6:e17278.
30. Brinks V, Jiskoot W, Schellekens H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res 28:2379-2385.
31. Perry LCA, Jones TD, Barker MP. 2008. New approaches to prediction of immune response to therapeutic proteins during preclinical development. Drugs R D 9:385-396.
32. Hermeling S, Jiskoot W, Crommelin D, Bornaes, C, Schellekens, H. 2005. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res 22:847-851.
33. Hermeling S, Aranha L, Damen, MA, Slijper, M, Schellekens, H, Crommelin, DJA, Jiskoot, W. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22:1997-2006.
34. Hermeling S, Schellekens H, Maas C, Gebbink, MFBG, Crommelin, DJA, Jiskoot, W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95:1084-1096.
35. Van Beers MMC, Sauerborn M, Gilli F, Brinks, V, Schellekens, H, Jiskoot, W. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28:2393-2402.
36. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3263.
37. Van Beers MMC, Sauerborn M, Gilli F, Brinks, V, Schellekens, H, Jiskoot, W. 2011. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27:1812-1824.
38. Van Beers, Gilli F, Schellekens H, Randolph TW, Jiskoot W. 2012. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal and polystyrene. J Pharm Sci 101:187-199.
39. Fradkin AH, Carpenter JF, Randolph TW. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100:4953-4963.
40. Rifkin RA, Maggio ET, Dike S, Kerr DA, Levy M. 2011. N-Dodecyl-β-d-maltoside inhibits aggregation of human interferon and reduces its immunogenicity. J Neuroimmune Pharmacol 6:158-162.
41. Mestas J, Hughes CCW. 2004. Of mice and not men: Differences between mouse and human immunology. J Immunol 172:2731-2738.